Abstract
The efficacy of anticancer therapy is limited by the development of drug resistance. While the role of p53 in the intrinsic sensitivity of human cancer cells to paclitaxel (PTX) remains controversial, its role in acquired paclitaxel resistance has never been addressed. In this study we examined the p53 status of three paclitaxel selected human ovarian carcinoma sublines, resistant to paclitaxel due to acquired β-tubulin mutations which impair paclitaxel's interaction with tubulin. In contrast to parental cells which have wt p53, in all PTX-resistant sublines p53 was functionally inactive. Two of the resistant sublines expressed high levels of transcriptionally inactive p53 protein, each with a distinct point mutation in codons 236 and 239 of the DNA binding domain. The third subline presented a novel p53 pseudo-null phenotype as a result of markedly decreased wt p53 mRNA expression. Introduction of ectopic wt p53 had no effect on PTX sensitivity in both parental and resistant cells, while it induced p21WAF1/CIP1, demonstrating an intact p53 pathway. While PTX resistance is primarily conferred by the tubulin mutations, the loss of functional p53 observed in all clones, suggests that this loss may facilitate the development of resistance potentially by providing a clonal advantage which promotes the isolation of paclitaxel resistant cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- wt:
-
wild-type
- PTX:
-
paclitaxel
- MOI:
-
multiplicity of infection
- PFU:
-
plaque forming units
- Ad-p53:
-
adenovirus expressing wt p53
- Ad-LacZ:
-
adenovirus expressing β-galactosidase
References
Blagosklonny MV . 1997 Oncogene 15: 1889–1893.
Blagosklonny M V and el-Deiry WS. . 1996 Int. J. Cancer 67: 386–392.
Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE and Fojo T. . 1998 J. Clin. Endocrinol. Metab. 83: 2516–2522.
Brachmann RK, Vidal M and Boeke JD. . 1996 Proc. Natl. Acad. Sci. USA 93: 4091–4095.
Cahill DP, Kinzler KW, Vogelstein B and Lengauer C. . 1999 Trends Cell Biol. 9: 57–60.
Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH and Reid BJ. . 1995 Science 267: 1353–1356.
Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M and Broggini M. . 1997 Cancer Res. 57: 870–874.
Dumontet C and Sikic BI. . 1999 J. Clin. Oncol. 17: 1061–1070.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.
Fan S, Cherney B, Reinhold W, Rucker K and O'Connor PM. . 1998 Clin. Cancer Res. 4: 1047–1054.
Fukasawa K, Choi T, Kuriyama R, Rulong S and Vande WG. . 1996 Science 271: 1744–1747.
Gan Y, Wientjes MG, Schuller DE and Au JL. . 1996 Cancer Res. 56: 2086–2093.
Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T and Poruchynsky MS. . 1997 J. Biol. Chem. 272: 17118–17125.
Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC and Fojo T. . 2000 Proc. Natl. Acad. Sci. USA 97: 2910–2915
Hartwell L. . 1992 Cell 71: 543–546.
Havre PA, Yuan J, Hedrick L, Cho KR and Glazer PM. . 1995 Cancer Res. 55: 4420–4424.
Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J and Haas M. . 1994a Am. J. Pathol. 145: 702–714.
Hsiao MH, Yu AL, Yeargin J, Ku D and Haas M. . 1994b Blood 83: 2922–2930.
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW. . 1991 Cancer Res. 51: 6304–6311.
Lengauer C, Kinzler KW and Vogelstein B. . 1998 Nature 396: 643–649.
Levine AJ. . 1997 Cell 88: 323–331.
Liu PK, Kraus E, Wu TA, Strong LC and Tainsky MA. . 1996 Oncogene 12: 2267–2278.
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T. . 1994 Science 266: 807–810.
Miyashita T and Reed JC. . 1995 Cell 80: 293–299.
Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY and Martin C. . 1999 J. Clin. Oncol. 17: 1786–1793.
Murphy LD, Herzog CE, Rudick JB, Fojo AT and Bates SE. . 1990 Biochemistry 29: 10351–10356.
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S and Devilee P. . 1989 Nature 342: 705–708.
O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJJ and Kohn KW. . 1997 Cancer Res. 57: 4285–4300.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR. . 1990 J. Natl. Cancer Inst. 82: 1107–1112.
Vasey PA, Jones NA, Jenkins S, Dive C and Brown R. . 1996 Mol. Pharmacol. 50: 1536–1540.
Wahl, AF, Donaldson, KL, Fairchild, C, Lee, FY, Foster, SA, Demers, GW and Galloway, DA.. 1996 Nat. Med. 2: 72–79.
Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Paull KD. . 1997 Science 275: 343–349.
Zhang CC, Yang JM, White E, Murphy M, Levine A and Hait WN. . 1998 Oncogene 16: 1617–1624.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giannakakou, P., Poy, G., Zhan, Z. et al. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19, 3078–3085 (2000). https://doi.org/10.1038/sj.onc.1203642
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203642
Keywords
This article is cited by
-
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial
Cancer Chemotherapy and Pharmacology (2015)
-
Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response
Cell Death & Differentiation (2014)
-
Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck
Head and Neck Pathology (2014)
-
Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy
Medical Oncology (2013)
-
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
British Journal of Cancer (2012)